Global Radiopharmaceuticals/Nuclear Medicine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: pbi
Veröffentlicht am: 15.02.2018 07:31
Rubrik: Urlaub & Reise


(Presseportal openBroadcast) - Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:
Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-4H8Z4LpNMLEuOnnx


Global Radiopharmaceuticals/Nuclear Medicine Market:

Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radiotherapeutic and diagnostic procedures across the globe.

Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe

The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period

Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis

The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-c654SbFYO64MsOhu


North America accounts for larger revenue share in global radiopharmaceuticals market

North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region


Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-14mlyhjMGhVjZqa3


Competition Assessment

Key players profiled in the global Radiopharmaceuticals market include:
• Advanced Accelerator Applications S.A. (France)
• Bayer AG (Germany)
• Bracco Imaging S.p.A (Italy)
• Cardinal Health, Inc. (U.S.)
• Eli Lilly and Co. (U.S.)
• GE Healthcare (U.S.)
• IBA Molecular Imaging (Belgium)
• Jubilant Life Sciences Ltd (India)
• Lantheus Medical Imaging, Inc. (U.S.)
• Mallinckrodt plc (Ireland)
• Navidea Biopharmaceutical (U.S.)
• Nordion, Inc. (Canada)
• Siemens Healthineers (Germany)
Players in the radiopharmaceuticals market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals market.



Key Findings of the Report:

• Global Radiopharmaceuticals market expanding at 8.9% CAGR over 2017 to 2023 to reach market value of US$ 8,564 Mn by 2023
• Based on product type, diagnostic radiopharmaceuticals accounted for larger market revenue share in 2016 owing to wider application in various diagnostic procedures across the regions and expected to grow at significant rate
• Oncology application segment accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period owing to growing prevalence of various cancers
• Players are focusing on production of radiopharamceuticals to expand market presence in global radiopharmaceuticals market.
Key Features of the Report:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/

Pressekontakt:

Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.